4Markman M, Kennedy A, Webster K, et al. Paclitaxel-associated hypersensitivity reactions : experience of the gyneeologic ontology program of the Cleveland Clinic Cancer Center[ J]. J ClinOncol, 2000, 18(1) :102 -105.
5Denman JP, Gilbar PJ, Abdi EA. Hypersensitivity Reaction (HSR) to Docetaxel After a Previous HSR to Paclitaxel[ J]. J Clin Oncol, 2002,20( 11 ) :2760 - 2761.
6Kim JG,Sohn SK,Chae YS,et al. Muhicenter phase Ⅱ study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group[J ] .Br J Cancer, 2008, 98 (3) :542.
7Kang Y, Kang WK, Shin DB,et al. Randomized phase Ⅲ trial of capecitabine/ cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first- line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results[J ] .Proc Am Soc Clin Oncol , 2006,24(18) : 4 018.
8Cunningham MD, Rao S, Starling N,et al. Randomised multicentre phase Ⅲ study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer. The RE- AL 2 trial[J ]. Proc Am Soc Clin Oncol, 2006, 24(18) : 4 017.
9Thuss- Patience PC, Kretzschmar A, Dogan Y, et al. Capecitabine and docetaxel for advanced gastric cancer [J ] .J Clin Oncol, 2006,24(18): 4 068.
